This is the authors' abstract. We don't add key points for this paper.
We read the article by Shah et al. titled, SMAD4: A case-based review of the literature and current treatment options published in your esteemed journal with great interest.[1] The authors discussed the possible molecular genomic profiling-based treatment options for the patient and suggested the potential role of ‘mothers against decapentaplegic homolog 4’ (SMAD4) as a prognostic biomarker in lung adenocarcinoma. While we greatly appreciated the article, we identified a few discrepancies in the clinical decision-making by the molecular tumor board. First, the patient’s histopathology report was neglected, and insufficient attention was given to conducting a comprehensive immunohistochemistry (IHC) analysis (apart from distinguishing primary from secondary lung adenocarcinoma).[2] This could have helped in the selection of the appropriate first-line chemotherapy and could have affected the treatment outcomes as well. Next, the authors described the role of SMAD4 and transforming growth factor (TGF) signaling pathway in lung cancer, which is well described in the literature as a poor prognostic marker by Wang et al.[3] Rather than SMAD4, the authors should have focused on the well-established pathogenic mutation, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (potential driver or combination approach), to take clinical decisions even though, thus far, the PI3K inhibitors have not led to exciting outcomes, as observed by Baa et al.[4] PIK3CA, encoding p110α, and most of its hotspot mutations are clustered in the helical domain or the kinase domain. PIK3CA hotspot mutation is well established as an oncogenic driver event in lung cancer. Hao et al.[5] observed that the pathogenic mutation in the p110α helical domain disassociates the p85β subunit and enriches its translocation into the nucleus to enhance H3K27 trimethylation. According to Chen et al.,[6] a combination of alpelisib, a p110α-specific inhibitor, and an enhancer of zeste homolog 2 (EZH2) inhibitor, tazemetostat, induces regression of xenograft tumors, harboring a PIK3CA helical domain mutation. The second option would be inhibiting the TGF signaling pathway with dasatinib (Yes-associated protein [YAP] or transcriptional co-activator with PDZ-binding motif [TAZ] inhibitor) along with tazemetostat as a synergistic drug for metastatic recurrent non-small cell lung cancer (NSCLC), as noted by Lo Sardo et al.[7] Furthermore, the purpose of the molecular tumor board is not well understood, since it did not suggest the treatment plan for the patient beyond the National Comprehensive Cancer Network (NCCN)-recommended guidelines even after the second line of treatment. Moreover, both the pathologist’s and the genomicist’s views were missed in this comprehensive genomic profiling-based personalized cancer treatment plan formulated through the molecular tumor board. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Silambarasan Maskomani (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: